NCT06028633 2023-09-13Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsPeking University First HospitalPhase 2 Not yet recruiting28 enrolled